Salivary Gland Neoplasms: all 159 studies

Page 1 of 2. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.

• Abiraterone With Dalpiciclib in Salivary Gland CarcinomaRecruitingNCT07815522Phase 2
• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/2
• DESTINY-PANTUMOUR04RecruitingNCT07124000
• Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)RecruitingNCT06923826Phase 2
• A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland CancersRecruitingNCT06805617Phase 2
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingNCT06695845Phase 2
• PDO Based Drug Sensitive Test in R/M SGCRecruitingNCT06686979
• Oropharynx (OPX) Biomarker TrialRecruitingNCT06356272
• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
• Immune Biomarker Study for Salivary Gland CarcinomaRecruitingNCT06047236
• Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter StudyRecruitingNCT05946577
• A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsRecruitingNCT05941507Phase 1/2
• Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDCNot yet recruitingNCT05898373Phase 1/2
• Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersRecruitingNCT05884320Phase 2
• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/3
• Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland CarcinomaRecruitingNCT05727410Phase 2
• Drug Screening Using Novel IMD in Salivary and Head and Neck CancersRecruitingNCT05553782Early Phase 1
• The Head and Neck Registry of the European Reference Network on Rare Adult Solid CancersRecruitingNCT05483374
• Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 2
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsRecruitingNCT05000892Phase 2
• Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant NeoplasmsNot yet recruitingNCT04825938Phase 2
• Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingNCT04620187Phase 2
• Physiologic MR Imaging of Salivary Gland TumorsRecruitingNCT04452162Not applicable
• Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma PatientsRecruitingNCT03924466Phase 2
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsRecruitingNCT03740256Phase 1
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/2
• Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal VolunteersRecruitingNCT00900419
• Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy ParticipantsRecruitingNCT00898638
• Amivantamab in Adenoid Cystic CarcinomaActive, not recruitingNCT05074940Phase 2Results posted
• 9-ING-41 Plus Carboplatin in Salivary Gland CarcinomaActive, not recruitingNCT05010629Phase 2Results posted
• MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland CancerActive, not recruitingNCT04895735Phase 2Results posted
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted
• A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaActive, not recruitingNCT04325828Phase 2Results posted
• Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersCompletedNCT03749460Phase 1/2Results posted
• Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerCompletedNCT03172624Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerActive, not recruitingNCT03146650Phase 2Results posted
• Enzalutamide for Patients With Androgen Receptor Positive Salivary CancersActive, not recruitingNCT02749903Phase 2Results posted
• Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck CancerCompletedNCT02589938Not applicableResults posted
• Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryCompletedNCT02538510Phase 1/2Results posted
• Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation TherapyCompletedNCT02123511Phase 2Results posted
• PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT01816984Phase 1/2Results posted
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyCompletedNCT01806675Phase 1/2Results posted
• Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland CancerCompletedNCT01613768Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaCompletedNCT01604772Phase 2Results posted
• Stereotactic Body Radiotherapy for Head and Neck TumorsCompletedNCT01344356Phase 4Results posted
• Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous TherapyCompletedNCT01256385Phase 2Results posted
• Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic CarcinomaCompletedNCT01175980Phase 2Results posted
• Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckCompletedNCT01044433Phase 2Results posted
• Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabCompletedNCT00939627Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsCompletedNCT00859937Phase 2Results posted
• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT00588770Phase 3Results posted
• Iressa Study in Patients With Salivary Gland CancerCompletedNCT00509002Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00095628Phase 2Results posted
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2Results posted
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 1
• Enhanced Assistance During Radiotherapy for Unmet Essential NeedsCompletedNCT06582849Not applicable
• Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland CancersStatus unknownNCT06091878
• Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.CompletedNCT06034782
• Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)CompletedNCT05694819Phase 2
• Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersActive, not recruitingNCT05669664Phase 2
• A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck CancerActive, not recruitingNCT05608876Phase 2
• Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2Status unknownNCT05601401Phase 2
• PSMA-PET Imaging of Salivary Gland Tumours and Other Rare CancersCompletedNCT05581979
• Survival With Patients Treated With Salivary Gland CancerCompletedNCT05390294
• Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）Status unknownNCT05087706
• Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT StudyActive, not recruitingNCT05075980Phase 2
• Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland CarcinomasStatus unknownNCT05013515Not applicable
• Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II StudyStatus unknownNCT05008237Phase 2
• Partial Modified Blair Incision on Benign Tumor Parotidectomy Scar's CharacteristicsCompletedNCT04970875
• A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid TumoursActive, not recruitingNCT04969835Phase 1
• Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland TumoursCompletedNCT04907422
• 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaWithdrawnNCT04832438Phase 2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer PatientsCompletedNCT04291300Phase 2
• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)TerminatedNCT04249947Phase 1
• PSMA-PET Imaging Before and After ADT in Advanced SDC PatientsStatus unknownNCT04214353Not applicable
• Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
• The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
• Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaActive, not recruitingNCT03942653Phase 2
• Cell-free Tumor DNA in Head and Neck Cancer PatientsStatus unknownNCT03942380Not applicable
• APG-115 in Salivary Gland Cancer TrialActive, not recruitingNCT03781986Phase 1/2
• Cabozantinib in Advanced Salivary Gland Cancer PatientsTerminatedNCT03729297Phase 2
• Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland CarcinomasStatus unknownNCT03687294
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneCompletedNCT03602079Phase 1/2
• Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland TumorsActive, not recruitingNCT03360890Phase 2
• PSMA-PET Imaging for Advanced ACC/SDCCompletedNCT03319641Not applicable
• Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and NeckCompletedNCT03132038Phase 2
• Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland TumorsCompletedNCT02921984Phase 1
• Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland CancersCompletedNCT02867852Phase 2
• Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14CompletedNCT02860936Phase 2
• Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14CompletedNCT02857712Phase 2
• Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland CarcinomasCompletedNCT02776163Phase 2
• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsActive, not recruitingNCT02650401Phase 1/2
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2

← Salivary Gland Neoplasms overview